On Thursday, Sprouts Farmers Market Inc (NASDAQ:SFM)’s shares inclined 0.38% to $21.03.
Sprouts Farmers Market, Inc. (the “Company”) (SFM) stated results for its 13-week second quarter ended June 28, 2015.
Second Quarter Highlights:
- Net sales of $902.2 million; a 21% enhance from the same period in 2014
- Comparable store sales growth of 5.1% and two-year comparable store sales growth of 14.6%
- Net income of $31.3 million and diluted earnings per share of $0.20
- Adjusted net income of $35.0 million; a 16% enhance from the same period in 2014
- Adjusted diluted earnings per share of $0.22; a 10% enhance from the same period in 2014
- Adjusted EBITDA of $77.6 million; a 12% enhance from the same period in 2014
- New $450 million revolving credit facility; $160 million outstanding after $100 million voluntary pay down
Sprouts Farmers Market, Inc. operates as a specialty retailer of fresh, natural, and organic food in the United States. The company’s stores offer fresh produce, bulk foods, vitamins and supplements, grocery products, meat and seafood products, deli and bakery products, dairy and dairy alternatives, frozen foods, beer and wine, natural health and body care products, and natural household products. As of May 7, 2015, it operated 205 stores in 12 states. Sprouts Farmers Market, Inc. was founded in 2002 and is based in Phoenix, Arizona.
AFLAC Incorporated(NYSE:AFL)’s shares dropped -2.85% to $61.25.
Aflac Incorporated’s board of directors has authorized the purchase of up to 40 million shares of its common stock. This authorization is in addition to the 16.0 million shares that remained under a previous authorization as of June 30, 2015, bringing the total number of shares accessible for purchase to about 56.0 million. The company anticipates that the repurchase of shares will be conducted from time to time in open market or negotiated transactions, depending on market conditions.
Aflac Incorporated, through its partner, American Family Life Assurance Company of Columbus, provides supplemental health and life insurance products. It operates through two segments, Aflac Japan and Aflac U.S. The Aflac Japan segment offers various voluntary supplemental insurance products, counting cancer plans, general medical indemnity plans, medical/sickness riders, care plans, living benefit life plans, ordinary life insurance plans, and annuities in Japan.
At the end of Thursday’s trade, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)‘s shares dipped -6.95% to $2.81.
Arena Pharmaceuticals, Inc. (ARNA) stated financial results for the second quarter ended June 30, 2015, and offered a corporate update.
Second Quarter and Recent Developments
Arena Research & Development
- Declared the initiation of patient screening in a Phase 2 proof-of-concept clinical trial of APD334, an oral Sphingosine 1-Phosphate Subtype 1 (S1P1) receptor modulator for autoimmune diseases, being studied in this trial for the treatment of ulcerative colitis.
- Arena and Roivant Sciences Ltd. reached a Development, Marketing and Supply Agreement for nelotanserin, Arena’s internally discovered inverse agonist of the serotonin 2A receptor.
- Declared results from a Phase 1 single-ascending dose clinical trial of APD371, a highly selective and potent cannabinoid 2 (CB2) receptor agonist in development as a potential treatment for pain.
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight administration in adults. It is also developing a portfolio of programs in various therapeutic areas, counting cardiovascular, central nervous system, and metabolic diseases. Its products under development comprise Ralinepag, an agonist of the prostacyclin receptor intended for the treatment of vascular diseases, counting potentially pulmonary arterial hypertension that is in Phase II clinical trials.
News Corp(NASDAQ:NWSA), ended its Thursday’s trading session with -5.12% loss, and closed at $14.26.
HarperCollins Publishers, a partner of News Corp (NWSA) and joint venture partner Ediouro Group recently declared the formation of HarperCollins Brasil, which combines the existing operations of Thomas Nelson Brasil and Harlequin Brasil with Ediouro’s commercial trade publishing titles and personnel.
HarperCollins Brasil will publish a select list of about 350 titles per year from the HarperCollins trade, children’s, Christian and romance imprints from around the world, in addition to a focused list of Brazilian authors. The new structure aligns Brazil with the HarperCollins strategy to build on existing infrastructures and relationships to grow its authors’ international presence and publish outside of the English language, as has been done in Germany, Poland, Nordic, Holland, Japan and Spain.
News Corporation, a media and information services company, focuses on creating and distributing authoritative and engaging content to consumers and businesses worldwide. The company operates through News and Information Services, Cable Network Programming, Digital Real Estate Services, Book Publishing, and Digital Education segments. The News and Information Services segment offers print and digital products, counting The Wall Street Journal, Barrons, and other publications; and Marketwatch.com, in addition to a suite of professional information products, counting Factiva, Dow Jones Risk & Compliance, Dow Jones Newswires, Dow Jones Private Markets, and DJX. This segment also provides free-standing inserts, in-store marketing products and services, and digital marketing solutions to consumer packaged goods advertisers in the United States and Canada.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
